We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Rigel

News List

Rigel bags first FDA approval pharmatimes
July 16, 2018
Rigel Pharmaceuticals has bagged its first FDA approval, with a green light to market Tavalisse for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have failed to respond to previous treatment.
Rigel Pharma Awaits FDA Approval for Tavalisse, Builds Commercial Org for Drug Launch biospace
January 16, 2018
As the company is awaiting the regulatory approval of a rare blood disease drug and has built an internal infrastructure to commercialize the product
Rigel submits new drug application to FDA for Fostamatinib in Chronic ITP europeanpharmaceuticalreview
April 19, 2017
Rigel Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for fostamatinib in patients with chronic and persistent immune thrombocytopenia (ITP).

Previous page 1 2 Next page